RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Relay Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$17.09+0.81 (+4.98%)
Close on Oct 19, 2026
- Market cap
- $3.47B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
247M of 219M shares
Institutional holders
258
51 new, 31 sold out
Net institutional buying
62M
In Q2 2026
Insider trades, 12 months
0 buys · 38 sales
Net sold $129.02M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Point72 Capital Advisors, Inc. | 9,694,217 | 5.70% | 13G (passive) | Mar 14, 2025 |
| Joseph Edelman | 438,471 | 9.99% | 13G (passive) | Apr 6, 2026 |
| FMR LLC | 21,270,751 | 10.00% | 13G (passive) amendment | Jul 31, 2026 |
| Perceptive Advisors LLC | 14,106,187 | 6.40% | 13G (passive) amendment | Jun 30, 2026 |
| Point72 Asset Management, L.P. | 13,445,704 | 7.80% | 13G (passive) amendment | Jun 30, 2025 |
| Michael Kramarz | 13,350,000 | 7.80% | 13G (passive) amendment | Jun 30, 2025 |
| Eli Casdin | 13,003,574 | 7.50% | 13G (passive) amendment | Dec 31, 2025 |
| Casdin Capital, LLC | 13,003,574 | 7.50% | 13G (passive) amendment | Dec 31, 2025 |
| Robert Egen Atkinson | 12,000,000 | 5.50% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 10,308,012 | 6.10% | 13G (passive) amendment | Mar 31, 2025 |
| Commodore Capital Master LP | 10,000,000 | 5.80% | 13G (passive) | May 8, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RLAY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sb Investment Advisers (Uk) Ltd | 27,904,963 | 12.73% | $522.10M | – | 6.81% |
| FMR LLC | 20,110,113 | 9.18% | $376.26M | +16,414,682 | 0.02% |
| Casdin Capital, LLC | 16,035,240 | 7.32% | $300.02M | +1,616,666 | 15.02% |
| BlackRock, Inc. | 15,288,202 | 6.98% | $286.04M | +2,312,903 | 0.00% |
| Perceptive Advisors LLC | 14,106,187 | 6.44% | $263.93M | +4,355,046 | 3.96% |
| Commodore Capital LP | 12,000,000 | 5.48% | $224.52M | −5,000,000 | 13.37% |
| State Street Corp | 10,125,381 | 4.62% | $189.47M | +3,891,836 | 0.01% |
| Vanguard Capital Management LLC | 8,964,423 | 4.09% | $167.72M | +1,576,958 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 7,708,507 | 3.52% | $144.23K | +5,783,569 | 0.01% |
| Nextech Invest, Ltd. | 6,776,506 | 3.09% | $126.79M | +1,250,000 | 6.02% |
| Bellevue Group AG | 6,185,970 | 2.82% | $115.74M | −1,609,272 | 2.44% |
| Geode Capital Management, LLC | 4,726,576 | 2.16% | $88.45M | +1,215,940 | 0.00% |
| TCG Crossover Management, LLC | 4,273,356 | 1.95% | $79.95M | – | 1.92% |
| Alliancebernstein L.P. | 4,095,600 | 1.87% | $40.75M | +3,950,349 | 0.01% |
| Morgan Stanley | 3,851,071 | 1.76% | $72.05M | +2,419,068 | 0.00% |
| Siren, L.L.C. | 3,650,000 | 1.67% | $68.29M | New | 1.38% |
| Goldman Sachs Group Inc | 3,408,701 | 1.56% | $63.78M | +866,840 | 0.01% |
| Westfield Capital Management Co LP | 3,343,496 | 1.53% | $62.56M | New | 0.20% |
| Kynam Capital Management, LP | 3,300,000 | 1.51% | $61.74M | +1,875,741 | 3.41% |
| Dimensional Fund Advisors LP | 3,127,564 | 1.43% | $58.53M | +187,028 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 258 | 247M | 100.0% | 51 / 115 | 64 / 31 | 83M | 21M |
| Q1 2026 | 244 | 185M | 84.5% | 51 / 96 | 53 / 30 | 44M | 24M |
| Q4 2025 | 227 | 174M | 79.4% | 50 / 68 | 57 / 20 | 23M | 16M |
| Q3 2025 | 199 | 167M | 76.0% | 20 / 63 | 63 / 26 | 11M | 15M |
| Q2 2025 | 208 | 171M | 78.2% | 36 / 72 | 56 / 34 | 26M | 22M |
| Q1 2025 | 207 | 167M | 76.4% | 36 / 73 | 59 / 24 | 23M | 15M |
| Q4 2024 | 199 | 164M | 74.8% | 43 / 87 | 36 / 37 | 26M | 31M |
| Q3 2024 | 195 | 169M | 77.3% | 46 / 72 | 46 / 28 | 56M | 8M |
| Q2 2024 | 179 | 132M | 60.3% | 22 / 75 | 50 / 30 | 12M | 18M |
| Q1 2024 | 189 | 138M | 63.1% | 31 / 73 | 50 / 19 | 20M | 15M |
| Q4 2023 | 177 | 134M | 61.2% | 33 / 55 | 57 / 25 | 19M | 16M |
| Q3 2023 | 172 | 130M | 59.5% | 23 / 67 | 47 / 12 | 9M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RLAY | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 6,800,083 | 3.10% | $127.23M | 0.01% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 6,304,701 | 2.88% | $117.96M | 1.10% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,163,646 | 1.90% | $77.90M | 0.09% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,943,788 | 0.89% | $36.37M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 1,917,750 | 0.88% | $36.11M | 0.41% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 1,850,700 | 0.84% | $34.85M | 1.58% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,840,896 | 0.84% | $34.44M | 0.29% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,767,834 | 0.81% | $33.29M | 0.10% | Jul 31, 2026 |
| Harbor Small Cap Growth Fund | 1,681,000 | 0.77% | $31.65M | 1.19% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 1,680,415 | 0.77% | $31.64M | 0.43% | Jul 31, 2026 |
| Select Health Care Portfolio | 1,680,000 | 0.77% | $23.60M | 0.41% | May 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,574,152 | 0.72% | $29.45M | 0.20% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,366,611 | 0.62% | $25.57M | 0.26% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,285,400 | 0.59% | $18.06M | 0.01% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,128,810 | 0.52% | $21.12M | 0.14% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sanjiv Patel | President and CEO, Director | 1,406,403 | 0.64% | Sep 9, 2026 |
| Donald A. Bergstrom | President, R&D | 399,130 | 0.18% | Sep 9, 2026 |
| Thomas Catinazzo | Chief Financial Officer | 122,851 | 0.06% | Sep 9, 2026 |
| Peter Rahmer | See remarks | 223,657 | 0.10% | Aug 28, 2026 |
| Brian Adams | Chief Legal Officer | 371,472 | 0.17% | Jul 30, 2025 |
| Alexis Borisy | Director | 234,175 | 0.11% | Jun 10, 2026 |
| Mark Murcko | Director | 996,952 | 0.45% | Jun 10, 2026 |
| Claire Mazumdar | Director | – | – | Jun 10, 2026 |
| Habib J. Dable | Director | – | – | Jun 10, 2026 |
| Linda A. Hill | Director | – | – | Jun 10, 2026 |
| Lonnel Coats | Director | – | – | Jun 10, 2026 |
| Douglas S. Ingram | Director | 25,000 | 0.01% | Jun 10, 2026 |
| Sekar Kathiresan | Director | – | – | Jun 6, 2025 |
| Jami Rubin | Director | 67,242 | 0.03% | Jun 6, 2025 |
| Vision Fund (Aiv M2) L.P. Softbank | 10% owner | – | – | Aug 28, 2026 |
| Pauling (Cayman) Ltd SVF | 10% owner | 27,904,963 | 12.73% | Aug 28, 2026 |
| Investment Advisers (Uk) Ltd Sb | 10% owner | 21,904,963 | 10.00% | Aug 28, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Thomas Catinazzo Chief Financial Officer | Sep 8, 2026 | Sale(10b5-1 plan) | −17,717 | $18.94 | $335.56K | 122,851 |
| Donald A. Bergstrom President, R&D | Sep 8, 2026 | Sale(10b5-1 plan) | −8,530 | $18.97 | $161.81K | 399,130 |
| Sanjiv Patel President and CEO, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −48,199 | $18.94 | $912.89K | 519,500 |
| Peter Rahmer See remarks | Aug 26, 2026 | Sale(10b5-1 plan) | −4,508 | $20.03 | $90.30K | 223,657 |
| Investment Advisers (Uk) Ltd Sb 10% owner | Aug 25, 2026 | Sale | −6,000,000 | $19.40 | $116.40M | 21,904,963 |
| Sanjiv Patel President and CEO, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −48,199 | $20.33 | $979.89K | 567,699 |
| Thomas Catinazzo Chief Financial Officer | Aug 14, 2026 | Sale(10b5-1 plan) | −17,717 | $19.74 | $349.73K | 140,568 |
| Thomas Catinazzo Chief Financial Officer | Jul 28, 2026 | Sale | −1,459 | $18.61 | $27.15K | 158,285 |
| Donald A. Bergstrom President, R&D | Jul 28, 2026 | Sale | −2,237 | $18.61 | $41.63K | 407,660 |
| Peter Rahmer See remarks | Jul 28, 2026 | Sale | −748 | $18.61 | $13.92K | 228,165 |
| Sanjiv Patel President and CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −48,199 | $19.58 | $943.74K | 615,898 |
| Thomas Catinazzo Chief Financial Officer | Jul 6, 2026 | Sale(10b5-1 plan) | −17,717 | $18.69 | $331.13K | 159,744 |
| Donald A. Bergstrom President, R&D | Jul 6, 2026 | Sale(10b5-1 plan) | −8,660 | $18.71 | $162.03K | 409,897 |
| Sanjiv Patel President and CEO, Director | Jun 30, 2026 | Award | +3,056 | $6.95 | $21.24K | 664,097 |
| Peter Rahmer See remarks | Jun 30, 2026 | Sale(10b5-1 plan) | −50,000 | $19.09 | $954.50K | 225,857 |
| Peter Rahmer See remarks | Jun 30, 2026 | Award | +3,056 | $6.95 | $21.24K | 228,913 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −17,717 | $17.01 | $301.37K | 177,461 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Option exercise | +56,323 | $5.04 | $283.87K | 233,784 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −51,560 | $16.97 | $874.97K | 177,461 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Option exercise | +51,560 | $4.45 | $229.44K | 229,021 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −61,563 | $16.97 | $1.04M | 177,461 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Option exercise | +61,563 | $5.22 | $321.36K | 239,024 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −56,323 | $16.97 | $955.80K | 177,461 |
| Donald A. Bergstrom President, R&D | Jun 22, 2026 | Option exercise | +93,456 | $4.12 | $385.04K | 512,013 |
| Donald A. Bergstrom President, R&D | Jun 22, 2026 | Sale(10b5-1 plan) | −93,456 | $16.94 | $1.58M | 418,557 |
| Thomas Catinazzo Chief Financial Officer | May 14, 2026 | Sale(10b5-1 plan) | −17,717 | $12.86 | $227.84K | 195,178 |
| Donald A. Bergstrom President, R&D | Apr 28, 2026 | Sale | −1,490 | $14.79 | $22.04K | 418,557 |
| Peter Rahmer See remarks | Apr 28, 2026 | Sale | −753 | $14.79 | $11.14K | 275,857 |
| Thomas Catinazzo Chief Financial Officer | Apr 28, 2026 | Sale | −972 | $14.79 | $14.38K | 212,895 |
| Thomas Catinazzo Chief Financial Officer | Apr 9, 2026 | Option exercise | +1,800 | $5.22 | $9.40K | 215,667 |
| Thomas Catinazzo Chief Financial Officer | Apr 9, 2026 | Sale(10b5-1 plan) | −1,800 | $15.00 | $27.00K | 213,867 |
| Thomas Catinazzo Chief Financial Officer | Apr 7, 2026 | Sale(10b5-1 plan) | −17,717 | $13.01 | $230.50K | 213,867 |
| Thomas Catinazzo Chief Financial Officer | Mar 9, 2026 | Sale(10b5-1 plan) | −17,717 | $10.06 | $178.23K | 231,584 |
| Peter Rahmer See remarks | Jan 28, 2026 | Sale | −1,354 | $8.45 | $11.44K | 276,610 |
| Donald A. Bergstrom President, R&D | Jan 28, 2026 | Sale | −2,686 | $8.45 | $22.70K | 420,047 |
| Thomas Catinazzo Chief Financial Officer | Jan 28, 2026 | Sale | −1,695 | $8.45 | $14.32K | 249,301 |
| Peter Rahmer See remarks | Jan 27, 2026 | Sale | −11,684 | $7.62 | $89.03K | 277,964 |
| Donald A. Bergstrom President, R&D | Jan 27, 2026 | Sale | −18,895 | $7.62 | $143.98K | 422,733 |
| Thomas Catinazzo Chief Financial Officer | Jan 27, 2026 | Sale | −13,820 | $7.62 | $105.31K | 250,996 |
| Sanjiv Patel President and CEO, Director | Jan 6, 2026 | Sale | −43,168 | $7.82 | $337.57K | 661,041 |
| Peter Rahmer See remarks | Dec 31, 2025 | Award | +994 | $2.99 | $2.97K | 338,463 |
| Sanjiv Patel President and CEO, Director | Dec 31, 2025 | Award | +994 | $2.99 | $2.97K | 704,209 |
| Sanjiv Patel President and CEO, Director | Nov 3, 2025 | Sale | −62,073 | $7.00 | $434.51K | 703,215 |
| Peter Rahmer See remarks | Oct 29, 2025 | Sale | −21,394 | $7.50 | $160.46K | 337,469 |
| Thomas Catinazzo Chief Financial Officer | Oct 28, 2025 | Sale | −21,664 | $7.29 | $157.93K | 313,631 |
| Peter Rahmer See remarks | Oct 28, 2025 | Sale | −19,135 | $7.29 | $139.49K | 358,863 |
| Donald A. Bergstrom President, R&D | Oct 28, 2025 | Sale | −30,897 | $7.29 | $225.24K | 521,823 |
| Brian Adams Chief Legal Officer | Jul 29, 2025 | Sale | −18,276 | $3.68 | $67.26K | 371,472 |
| Thomas Catinazzo Chief Financial Officer | Jul 29, 2025 | Sale | −18,380 | $3.68 | $67.64K | 335,295 |
| Peter Rahmer See remarks | Jul 29, 2025 | Sale | −15,724 | $3.68 | $57.86K | 377,998 |
| Donald A. Bergstrom President, R&D | Jul 29, 2025 | Sale | −26,701 | $3.68 | $98.26K | 552,720 |
| Brian Adams Chief Legal Officer | Jul 28, 2025 | Sale | −1,637 | $3.74 | $6.12K | 389,748 |
| Thomas Catinazzo Chief Financial Officer | Jul 28, 2025 | Sale | −1,701 | $3.74 | $6.36K | 353,675 |
| Peter Rahmer See remarks | Jul 28, 2025 | Sale | −1,359 | $3.74 | $5.08K | 393,722 |
| Donald A. Bergstrom President, R&D | Jul 28, 2025 | Sale | −4,069 | $3.74 | $15.22K | 579,421 |
| Sanjiv Patel President and CEO, Director | Jul 9, 2025 | Sale | −42,740 | $3.57 | $152.58K | 783,927 |
| Sanjiv Patel President and CEO, Director | Jul 9, 2025 | Sale | −18,639 | $3.57 | $66.54K | 765,288 |
| Peter Rahmer See remarks | Jun 30, 2025 | Award | +5,000 | $2.94 | $14.70K | 395,081 |
| Sanjiv Patel President and CEO, Director | Jun 30, 2025 | Award | +5,000 | $2.94 | $14.70K | 826,667 |
| Brian Adams Chief Legal Officer | Apr 30, 2025 | Sale | −12,943 | $3.00 | $38.83K | 391,385 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Patel Sanjiv Director, Officer | Oct 7, 2026 | 96,401 | $1.81M | Oct 7, 2026 | Restricted Stock Units |
| Catinazzo Thomas Officer | Oct 6, 2026 | 93,153 | $1.81M | Oct 6, 2026 | Restricted and Performance Stock Units |
| Rahmer Peter Officer | Aug 26, 2026 | 50,000 | $1.03M | Aug 26, 2026 | Restricted Stock Units |
| Pauling (Cayman) Ltd SVF Stockholder | Aug 25, 2026 | 6,000,000 | $123.42M | Aug 25, 2026 | Acquired upon the automatic conversion of Series C Convertible Preferred Stock upon the closing of the Issuer's initial public offering. The shares were acquired and fully paid for in December 2018. |
| Kathiresan Sekar Director | Aug 4, 2026 | 42,225 | $826.47K | Aug 4, 2026 | Stock Option Exercise |
| Kathiresan Sekar Director | Jul 31, 2026 | 30,000 | $563.55K | Jul 31, 2026 | Stock Option Exercise |
| Kathiresan Sekar Director | Jul 21, 2026 | 30,000 | $594.41K | Jul 21, 2026 | Stock Option Exercise |
| Kathiresan Sekar Director | Jul 20, 2026 | 66,055 | $1.29M | Jul 20, 2026 | Stock Option Exercise |
| Patel Sanjiv Director, Officer | Jul 7, 2026 | 144,597 | $2.73M | Jul 7, 2026 | Restricted Stock Units |
| Rahmer Peter Officer | Jun 30, 2026 | 50,000 | $987.00K | Jun 30, 2026 | Performance Stock Units |
| Catinazzo Thomas Officer | Jun 22, 2026 | 204,880 | $3.25M | Jun 22, 2026 | Exercise of Stock Options |
| Bergstrom Donald Officer | Jun 22, 2026 | 110,646 | $1.76M | Jun 22, 2026 | Exercise of Stock Options |
| Catinazzo Thomas Officer | May 14, 2026 | 37,234 | $492.23K | May 14, 2026 | Restricted and Performance Stock Units |
| Catinazzo Thomas Officer | Mar 9, 2026 | 53,151 | $525.66K | Mar 9, 2026 | Restricted Stock Units |
| J. Rahmer Peter Officer | Oct 29, 2025 | 21,394 | $160.44K | Oct 29, 2025 | Restricted Stock |